Jennifer Lee - Sep 5, 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of North America
Signature
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Lee
Stock symbol
RYTM
Transactions as of
Sep 5, 2023
Transactions value $
-$142,228
Form type
4
Date filed
9/7/2023, 05:48 PM
Previous filing
Aug 9, 2023
Next filing
Nov 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $30.7K +4.52K +137.19% $6.80 7.81K Sep 5, 2023 Direct
transaction RYTM Common Stock Sale -$173K -6.17K -78.92% $28.05 1.65K Sep 5, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (Right to Buy) Options Exercise $0 -4.52K -6.26% $0.00 67.7K Sep 5, 2023 Common Stock 4.52K $6.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.
F2 The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $28.00 to $28.25. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
F3 The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.